Invivyd (IVVD)
Develops monoclonal antibodies for serious viral diseases, beginning with COVID-19 prevention.
Something off on this page? Send us feedback.
Develops and commercializes monoclonal antibodies for serious viral infectious diseases. PEMGARDA, its first authorized medicine, is used for COVID-19 pre-exposure prophylaxis; its commercial model depends on an emergency use authorization.
PEMGARDA is Invivyd’s first authorized medicine, a monoclonal antibody for COVID-19 pre-exposure prophylaxis in specified immunocompromised adults and adolescents. That authorization moved the company from clinical development into commercial-stage operations focused on serious viral infectious diseases.
Its INVYMAB platform combines viral surveillance, predictive modeling, and antibody engineering to generate antibodies as viral threats evolve. The business began with SARS-CoV-2, and PEMGARDA is its first commercial product.
PEMGARDA is authorized under an FDA emergency use authorization rather than conventional approval. Its authorization is scheduled to terminate unless the relevant regulatory situation changes.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Nov 25, 2025 | D. Boral Capital | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $160.1M · Total debt $8.4M · Total assets $218.9M · Shareholders' equity $181.1M
- Revenue
- $14.3M
- Operating income
- −$45.8M
- Net income
- −$44.4M
No dividends on record.
| Institutions | ≈ 78.97% | 232.76M shares | |
|---|---|---|---|
| 133 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 5.20% | 15.34M shares | |
| 8 holders · as of Aug 18, 2026 | |||
| Strategic holders | 6.87% | 20.26M shares | |
| 1 holder · as of Dec 29, 2025 | |||
| Other | ≈ 8.96% | 26.40M shares | |
| remainder | |||
294.76M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Jupiter Topco LLCInstitution | 11.59% | 34.17M | as of Jun 30, 2026 |
BVF Inc/ILInstitution | 9.56% | 28.17M | as of Jun 30, 2026 |
RA Capital Management, L.P.Institution | 7.24% | 21.34M | filed May 15, 2026 |
Adimab, LLC1,2Strategic10 percent owner | 6.87% | 20.26M | filed Dec 29, 2025 |
Maverick Capital LtdInstitution | 6.44% | 18.97M | as of Jun 30, 2026 |
- Adimab, LLC's transaction reports restate only vehicles that traded; the 2025 ownership statement (20.26M) is used instead.
- Adimab, LLC reports a block also reported by Perceptive Advisors LLC; it is counted once, under Perceptive Advisors LLC.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Robert D. III Allen | officer: Chief Scientific Officer | −17,043 | $0.8429 |
| Aug 17, 2026 | Robert D. III Allen | officer: Chief Scientific Officer | −20,679 | $0.7220 |
| Aug 18, 2026 | Jill Andersen | officer: Chief Legal Officer, Secretary | −30,706 | $0.8429 |
| Aug 17, 2026 | Jill Andersen | officer: Chief Legal Officer, Secretary | −37,256 | $0.7220 |
| Aug 18, 2026 | William E. Duke | officer: Chief Financial Officer | −18,425 | $0.8429 |
- AstraZeneca (ADR)
Active COVID-19 antibody program overlap
- Pfizer
Authorized oral COVID-19 antiviral overlap
- Merck
Authorized oral COVID-19 antiviral overlap
- Gilead Sciences
Authorized IV COVID-19 antiviral overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Invivyd | $0.9606 | −5.82% | $300.5M | — | — | 5.1 | +21.2% |
| AstraZeneca (ADR) | $168.44 | +0.20% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Pfizer | $27.83 | +0.32% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| Merck | $151.61 | +1.41% | $369.24B | 119.6 | 17.6 | 5.6 | +5.1% |
| Gilead Sciences | $152.61 | +1.36% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Median | 36.7 | 16.3 | 4.9 | +5.7% |